Last reviewed · How we verify
Atorvastatin-omeprazole
This is a fixed-dose combination of atorvastatin (a statin that lowers cholesterol) and omeprazole (a proton pump inhibitor that reduces stomach acid).
This is a fixed-dose combination of atorvastatin (a statin that lowers cholesterol) and omeprazole (a proton pump inhibitor that reduces stomach acid). Used for Hypercholesterolemia with concurrent need for gastric acid suppression, Cardiovascular risk reduction in patients requiring proton pump inhibitor therapy.
At a glance
| Generic name | Atorvastatin-omeprazole |
|---|---|
| Sponsor | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec |
| Drug class | Fixed-dose combination (statin + proton pump inhibitor) |
| Target | HMG-CoA reductase (atorvastatin); H+/K+-ATPase (omeprazole) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Atorvastatin inhibits HMG-CoA reductase to reduce LDL cholesterol and cardiovascular risk, while omeprazole suppresses gastric acid secretion by blocking the H+/K+-ATPase pump. The combination is designed to provide cardiovascular protection while reducing gastrointestinal side effects or acid-related conditions that may occur with statin therapy.
Approved indications
- Hypercholesterolemia with concurrent need for gastric acid suppression
- Cardiovascular risk reduction in patients requiring proton pump inhibitor therapy
Common side effects
- Headache
- Myalgia
- Gastrointestinal disturbance
- Diarrhea
Key clinical trials
- Study on the Effect of Atorvastatin Co-administered With Omeprazole on Statin Lactone (PHASE4)
- LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients (PHASE1)
- Pharmacokinetics of Clinical Probes and Characteristics of Endogenous Biomarker in Chinese Older Adults
- Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial. (NA)
- Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport (PHASE1)
- Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs (PHASE1)
- Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates (PHASE1)
- Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: